Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Michael Bitzer(University Children's Hospital Tübingen), Arndt Weinmann(Johannes Gutenberg University Mainz), Oliver Waidmann(Goethe University Frankfurt), Thorben Fründt(Universität Hamburg), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Fabian Kütting(University Hospital Cologne), Tobias Meischl(Medical University of Vienna), Harald Heinzl, Kornelius Schulze(Universität Hamburg), Fabian Finkelmeier(Goethe University Frankfurt), Katharina Pomej(Medical University of Vienna), Florian Hucke(Klinikum Klagenfurt), Johann von Felden(Universität Hamburg), Marc Stadler(Helmholtz Centre for Infection Research), Vera Himmelsbach(Goethe University Frankfurt), Martha M. Kirstein(University of Lübeck), Nuh N. Rahbari(Technische Universität Dresden), Nicola Personeni(IRCCS Humanitas Research Hospital), Stephan Spahn(University of Tübingen), Lorenza Rimassa(Humanitas University), Christian Müller(Medical University of Vienna), Sara De Dosso(Institute of Oncology Research), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Thomas Reiberger(ERN GUARD-Heart), Arndt Vogel(Princess Margaret Cancer Centre), Michael Trauner(Medical University of Vienna), Henning Wege(Universität Hamburg), Kateryna Shmanko(Johannes Gutenberg University Mainz), Andreas Teufel(Johannes Gutenberg University Mainz), Pompilia Radu(University of Bern), Lorenz Balcar(Medical University of Vienna), Jörg Trojan(Goethe University Frankfurt), Matthias P. Ebert(Heidelberg University), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Jean‐François Dufour(Universidad Iberoamericana), Alexander Siebenhüner(University Hospital Zurich), Mattias Mandorfer(Medical University of Vienna), Dirk‐Thomas Waldschmidt(University of Cologne), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 309
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k